Practical Recommendations for a Selection of Inhaled Corticosteroids in COPD: A Composite ICO Chart

The use of inhaled corticosteroids (ICS) for the maintenance of bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD) is controversial. While some patients achieve clinical benefits, such as fewer exacerbations and improved symptoms, others do not, and some experience undesired side effects, such as pneumonia. Thus, we reviewed the evidence related to predictors of ICS therapy treatment response in patients with COPD. The first priority clinical markers when considering the efficacy of ICS are type 2 inflammatory biomarkers, followed by a history of suspected asthma and recurrent exacerbations. It is also necessary to consider any potential infection risk associated with ICS, and several risk factors for pneumonia when using ICS have been clarified in recent years. In this article, based on the evidence supporting the selection of ICS for COPD, we propose an ICS composite that can be added to the COPD (ICO) chart for use in clinical practice. The chart divided the type 2 biomarkers into three ranges and provided recommendations (recommend, consider, and against) by combining the history of suspected asthma, history of exacerbations, and risk of infection.

[1]  C. McDonald,et al.  COPD‐X Australian guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2022 update , 2022, The Medical journal of Australia.

[2]  Meilan K. Han,et al.  Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission , 2022, The Lancet.

[3]  Meilan K. Han,et al.  Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review , 2022, Respiratory Research.

[4]  R. Dessau,et al.  Use of Inhaled Corticosteroids and Risk of Acquiring Haemophilus influenzae in Patients with Chronic Obstructive Pulmonary Disease , 2022, Journal of clinical medicine.

[5]  T. Hirano,et al.  Measurement of Blood Eosinophils in Asthma and Chronic Obstructive Pulmonary Disease , 2022, Internal medicine.

[6]  J. Wedzicha,et al.  A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid , 2022, International journal of chronic obstructive pulmonary disease.

[7]  J. Quint,et al.  Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study , 2022, International journal of chronic obstructive pulmonary disease.

[8]  S. Suissa,et al.  Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality , 2021, COPD.

[9]  M. Foreman,et al.  Eosinophilia and fractional exhaled nitric oxide levels in chronic obstructive lung disease , 2021, Thorax.

[10]  P. Dorinsky,et al.  Corrections to: Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts , 2021, Respiratory Research.

[11]  C. Vogelmeier,et al.  COPD Exacerbation History and Impact on Future Exacerbations – 8-Year Retrospective Observational Database Cohort Study from Germany , 2021, International journal of chronic obstructive pulmonary disease.

[12]  X. Hou,et al.  Blood eosinophil count-guided corticosteroid therapy and as a prognostic biomarker of exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis , 2021, Therapeutic advances in chronic disease.

[13]  R. Dessau,et al.  Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease , 2020, Thorax.

[14]  M. Ichinose,et al.  Asthma and Chronic Obstructive Pulmonary Disease Overlap According to the Japanese Respiratory Society Diagnostic Criteria: The Prospective, Observational ACO Japan Cohort Study , 2020, Advances in Therapy.

[15]  J. Wedzicha,et al.  Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study , 2020, American journal of respiratory and critical care medicine.

[16]  L. Koenderman,et al.  Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait , 2020, Thorax.

[17]  Y. Gon,et al.  Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease , 2020, Journal of clinical medicine.

[18]  P. Dorinsky,et al.  Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.

[19]  S. Aaron,et al.  Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for COPD: A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline. , 2020, Annals of the American Thoracic Society.

[20]  D. Price,et al.  Association between COPD exacerbations and lung function decline during maintenance therapy , 2020, Thorax.

[21]  F. Martinez,et al.  The effect of exacerbation history on outcomes in the IMPACT trial , 2020, European Respiratory Journal.

[22]  T. Hirano,et al.  Detection of type2 biomarkers for response in COPD , 2020, Journal of breath research.

[23]  S. Johnston,et al.  LONG TERM IMPACT OF INHALED CORTICOSTEROID USE IN ASTHMA AND COPD: REVIEW OF MECHANISMS THAT UNDERLIE RISKS. , 2020, The Journal of allergy and clinical immunology.

[24]  A. Agustí,et al.  Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection and Pneumonia Risk in Chronic Obstructive Pulmonary Disease: A Network Analysis. , 2020, American journal of respiratory and critical care medicine.

[25]  M. Obeidat,et al.  The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD , 2019, European Respiratory Journal.

[26]  S. Suissa,et al.  Comparative effects of LAMA-LABA-ICS versus LAMA-LABA for COPD: Cohort study in real world clinical practice: LAMA-LABA-ICS versus LAMA-LABA in COPD. , 2019, Chest.

[27]  O. Resta,et al.  Inhaled Corticosteroids And Risk Of Tuberculosis In Patients With Obstructive Lung Diseases: A Systematic Review And Meta-Analysis Of Non-randomized Studies , 2019, International journal of chronic obstructive pulmonary disease.

[28]  Meilan K. Han,et al.  Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. , 2019, The Lancet. Respiratory medicine.

[29]  C. Ulrik,et al.  COPD patients prescribed inhaled corticosteroid in general practice: Based on disease characteristics according to guidelines? , 2019, Chronic respiratory disease.

[30]  S. Suissa,et al.  Triple therapy trials in COPD: a precision medicine opportunity , 2018, European Respiratory Journal.

[31]  Wen-Lin Su,et al.  Treatment of chronic obstructive pulmonary disease in patients with different fractional exhaled nitric oxide levels , 2018, Medicine.

[32]  J. Wedzicha,et al.  Long‐Term Triple Therapy De‐escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double‐Blind, Triple‐Dummy Clinical Trial , 2018, American journal of respiratory and critical care medicine.

[33]  Y. Oh,et al.  Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary , 2018, Tuberculosis and respiratory diseases.

[34]  Meilan K. Han,et al.  Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.

[35]  M. Ichinose,et al.  Definition and diagnosis of asthma-COPD overlap (ACO). , 2018, Allergology international : official journal of the Japanese Society of Allergology.

[36]  N. Roche,et al.  Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial , 2018, The Lancet.

[37]  K. Matsunaga,et al.  Late-onset asthma: current perspectives , 2018, Journal of asthma and allergy.

[38]  S. Rennard,et al.  Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. , 2018, The Lancet. Respiratory medicine.

[39]  James R. Brown,et al.  Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations , 2018, Thorax.

[40]  A. Agustí,et al.  Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD , 2018, European Respiratory Journal.

[41]  H. Magnussen,et al.  Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease. , 2017, American journal of respiratory and critical care medicine.

[42]  N. Horita,et al.  Long-Acting β-Agonists (LABA) Combined With Long-Acting Muscarinic Antagonists or LABA Combined With Inhaled Corticosteroids for Patients With Stable COPD. , 2017, JAMA.

[43]  I. Pavord,et al.  Precision medicine in airway diseases: moving to clinical practice , 2017, European Respiratory Journal.

[44]  A. Spanevello,et al.  Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD , 2017, European Respiratory Journal.

[45]  J. Kwong,et al.  The risk of mycobacterial infections associated with inhaled corticosteroid use , 2017, European Respiratory Journal.

[46]  Jianping Zhao,et al.  GLCCI1 rs37973: a potential genetic predictor of therapeutic response to inhaled corticosteroids in Chinese chronic obstructive pulmonary disease patients , 2017, Scientific Reports.

[47]  R. Djukanović,et al.  Steroid-induced Deficiency of Mucosal-associated Invariant T Cells in the Chronic Obstructive Pulmonary Disease Lung. Implications for Nontypeable Haemophilus influenzae Infection. , 2016, American journal of respiratory and critical care medicine.

[48]  J. Wedzicha,et al.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.

[49]  H. Magnussen,et al.  Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. , 2016, The Lancet. Respiratory medicine.

[50]  F. Martinez,et al.  Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.

[51]  P. Calverley,et al.  Blood eosinophils as a marker of response to inhaled corticosteroids in COPD , 2016, European Respiratory Journal.

[52]  J. FitzGerald,et al.  Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta Analysis , 2015, PloS one.

[53]  F. Martinez,et al.  Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.

[54]  M. Decramer,et al.  Withdrawal of inhaled glucocorticoids and exacerbations of COPD. , 2014, The New England journal of medicine.

[55]  A. McKenzie,et al.  Type-2 innate lymphoid cells in human allergic disease , 2014, Current opinion in allergy and clinical immunology.

[56]  P. Jones,et al.  Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. , 2014, Respiratory medicine.

[57]  A. Corrado,et al.  Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO) , 2013, Respiratory Research.

[58]  H. Pinnock,et al.  Overtreatment of COPD with Inhaled Corticosteroids - Implications for Safety and Costs: Cross-Sectional Observational Study , 2013, PloS one.

[59]  K. Bracke,et al.  Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma , 2013, Nature Medicine.

[60]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[61]  H. Sørensen,et al.  Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis , 2012, Thorax.

[62]  D. Hoft,et al.  Polyclonal Mucosa-Associated Invariant T Cells Have Unique Innate Functions in Bacterial Infection , 2012, Infection and Immunity.

[63]  S. Suissa,et al.  Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality , 2012, Thorax.

[64]  A. Sharafkhaneh,et al.  Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. , 2012, Respiratory medicine.

[65]  S. Rennard,et al.  Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease , 2009, Drugs.

[66]  M. C. Rubio,et al.  Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable , 2012, Archivos de Bronconeumología.

[67]  M. Ichinose,et al.  Improvement of Airflow Limitation by Fluticasone Propionate/Salmeterol in Chronic Obstructive Pulmonary Disease: What is the Specific Marker? , 2011, Front. Pharmacol..

[68]  K. Rabe,et al.  Tiotropium versus salmeterol for the prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[69]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[70]  P. Barnes.  New therapies for asthma: is there any progress? , 2010, Trends in pharmacological sciences.

[71]  P. Jones,et al.  Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.

[72]  A. Anzueto,et al.  Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes , 2009, COPD.

[73]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[74]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[75]  A. Anzueto,et al.  Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. , 2008, Respiratory medicine.

[76]  C. P. Schayck,et al.  Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study. , 2008, Family practice.

[77]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[78]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[79]  C. Vogelmeier,et al.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[80]  F. Maltais,et al.  Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment , 2006, European Respiratory Journal.

[81]  M. Martínez-García,et al.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.

[82]  I. Pavord,et al.  Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease , 2005, Thorax.

[83]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[84]  J. Wedzicha,et al.  COPD exacerbations: definitions and classifications , 2003, European Respiratory Journal.

[85]  P. Jones,et al.  Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations , 2003, European Respiratory Journal.

[86]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[87]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[88]  W. Bailey,et al.  Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.

[89]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[90]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[91]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.